New hope for tough breast cancer: trial tests precision attack
NCT ID NCT05806060
Summary
This study is testing a new targeted drug, VEGFR BP102, combined with standard chemotherapy, against standard chemotherapy alone. It is for people with a specific, aggressive form of advanced triple-negative breast cancer (called the BLIS subtype) that has spread or cannot be surgically removed. The main goal is to see if the new combination can better control the cancer and delay its progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Breast cancer institute of Fudan University Cancer Hospital
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.